Summary
Risks associated with previously unknown, unrecognized, unanticipated, or unsuspected chemical pollutants in the environment have long been a major concern of environmental scientists. The importance of identifying such emerging risks is reflected in one of the top five goals of the Strategic Plan 2000 for the U.S. Environmental Protection Agency's (U.S. EPA) Office of Research and Development. Early identification and investigation of potential environmental pollution issues before they worsen are critical for protecting ecologic and human health. It is also important to rule out issues that could be of concern but prove otherwise, so that limited resources can be redirected. Ecosystem change is effected by human activities primarily via three routes: habitat fragmentation, alteration of community structure (e.g., via nonindigenous species), and chemical pollution. The scope of the former two is highly delineated and obvious compared with the latter. During the last three decades, the impact of chemical pollution has focused almost exclusively on the conventional "priority" pollutants. This group of chemicals, however, is only one piece of the larger puzzle.
One large class of chemicals receiving comparatively little attention comprises the pharmaceuticals and active ingredients in personal care products (PPCPs) , which are used in large amounts throughout the world; quantities of many are on par with agrochemicals. Escalating introduction to the marketplace of new pharmaceuticals is adding exponentially to the already large array of chemical classes, each with distinct modes of biochemical action, many of which are poorly understood. In contrast to agrochemicals, most of these products are disposed or discharged into the environment on a continual basis via domestic/industrial sewage systems and wet-weather runoff. The bioactive ingredients are first subjected to metabolism by the dosed user; the excreted metabolites and unaltered parent compounds can then be subjected to further transformations in sewage treatment facilities. The literature shows, however, that many of these compounds survive biodegradation, eventually being discharged into receiving waters; metabolic conjugates can even be converted back to their free parent forms. Many of these PPCPs and their metabolites are ubiquitous and display persistence in, and bioconcentration from, surface waters on par with those of the widely recognized organochlorine pollutants. Additionally, by way of continual infusion into the aquatic environment, those PPCPs that might have low persistence can display the same exposure potential as truly persistent pollutants since their transformation/removal rates can be compensated by their replacement rates.
Although certain biochemical actions of many drugs in humans have been elucidated, these actions are not necessarily always the ones responsible for the purported physiologic target effects. Sometimes the known pathways of action may have nothing to do with the actual desired effect, as the actual mechanism remains totally unknown. Understanding of the complex biochemical signaling pathways is currently too limited to design drugs that act only via targeted routes, and even then, if their activity can be limited to a single type of receptor, the tissue distribution of the receptor may not be fully known. Unpredicted and unknown side effects are often the norm. The possible actions and biochemical ramifications on nontarget aquatic biota are even less understood; many are totally unknown. The few that are known to elicit subtle but dramatic effects on aquatic life at very low concentrations, however, may point to an ill-defined vulnerability in aquatic ecosystems. A major concern is not necessarily acute effects to nontarget species (effects amenable to monitoring once they are understood), but rather the manifestation of perhaps imperceptible effects that can accumulate over time to ultimately yield truly profound changes-those whose causes would be obscured by time and that would not be distinguishable from natural events. The specter of subtle, cumulative effects could reduce the usefulness of current toxicity-directed screening methods in testing waste effluents for toxicologic end points due to PPCPs. Subtle effects, from low concentrations of bioactive PPCPs, whose continual expression over long periods of time in certain nontarget populations, could lead to cumulative, insidious, adverse impacts that would otherwise be attributed to natural change/
Introduction
For the purposes of this discussion, pharmaceutical (and veterinary and illicit) drugs (and the ingredients in cosmetics, food supplements, and other personal care products), together with their respective metabolites and transformation products, will collectively be referred to as pharmaceuticals and personal care products. PPCPs are continually infused into the environment via sewage treatment facilities and wet weather runoff. In many instances, untreated sewage is discharged into receiving waters (e.g., flood overload events, domestic "straight-piping," or sewage waters lacking municipal treatment). In the United States alone, possibly more than a million homes do not have sewage systems but instead rely on direct discharge of raw sewage into streams by straight-piping or by outhouses not connected to leach fields (1) . A number of Canadian cities are reported to discharge 3.25 billion liters per day (over 1 trillion liters per year) of essentially untreated sewage into surface waters and the ocean (2) . Raw/treated sewage is also disposed of from some locales in the deep ocean where it may possibly remix with upper waters.
We hope that this overview of PPCPs in the environment will a) catalyze a concerted effort among environmental chemists and ecotoxicologists to survey sewage treatment effluents, surface waters/groundwaters, and potable water for the presence of PPCPs and their bioactive transformation products and to determine their origins; b) elucidate the spectrum of possible physiologic effects of PPCPs on nontarget species, especially those that are aquatic; and c) promote discussion of whether this is an environmental issue deserving further investigation. We believe that a scientific debate on this topic is warranted given the evidence that has been accumulating over the last two decades on the occurrence of various pharmaceuticals in sewage effluent and in both surface waters and groundwaters. The big unknown is whether the combined low concentrations from each of the numerous PPCPs and their transformation products have any significance with respect to ecologic function, while recognizing that immediate effects could escape detection if they are subtle and that long-term cumulative consequences could be insidious. Another question is whether the pharmaceuticals remaining in water used for domestic purposes poses long-term risks for human health after lifetime ingestion via potable waters multiple times a day of very low, subtherapeutic doses of numerous pharmaceuticals; this issue, however, is not addressed in this review.
The hypothesis is further complicated by the fact that while the concentration of individual drugs in the aquatic environment could be low (sub-parts per billion or sub-nanomolar, often referred to as micropollutants), the presence of numerous drugs sharing a specific mode of action could lead to significant effects through additive exposures. It is also significant that drugs, unlike pesticides, have not been subjected to the same scrutiny regarding possible adverse environmental effects. They have therefore enjoyed several decades of unrestricted discharge to the environment, mainly via sewage treatment works. This is surprising especially since certain pharmaceuticals are designed to modulate endocrine and immune systems and cellular signal transduction and as such (as opposed to pesticides and other industrial chemicals already undergoing scrutiny as endocrine disruptors) have obvious potential as endocrine disruptors in the environment.
Exposure to PPCPs in the environment, especially for aquatic organisms, may differ from that of pesticides and other industrial chemicals in one significant respect-exposures may be of a more chronic nature because PPCPs are constantly infused into the environment wherever humans live or visit, whereas pesticide fluxes are more sporadic and have greater spatial heterogeneity. It is quite apparent that little information exists from which to construct comprehensive risk assessments for the vast majority of PPCPs having the potential to enter the environment.
Although little is known of the occurrence and effects of pharmaceuticals in the environment, more data exist for antibiotics than for any other therapeutic class. This is a result of their extensive use in both human therapy and animal husbandry, their more easily detected effects end points (e.g., via microbial and immunoassays), and their greater chances of introduction into the environment, not just by sewage treatment plants, but also by run-off and groundwater contamination, especially from confined animal feeding operations (CAFOs). The literature on antibiotics is much more developed because of the obvious issues of direct effects on native microbiota (and consequent alteration of microbial community structure) and development of resistance in potential human pathogens. Because of the considerably larger literature on antibiotics, this review only touches on the issue; for the same reason, this discussion only touches on steroidal drugs (those purposefully designed to modulate endocrine systems).
For the purposes of this document, pharmaceuticals will refer to nonbiologic drugs (i.e., those that do not comprise proteinaceous or nucleotide material). The number of biologics approved by the U.S. Food and Drug Administration (FDA) is growing, and their fate in the environment is unknown. This overview covers only a subset of the commercially available classes of pharmaceuticals and active ingredients in personal care products. The subset of classes discussed in this review comprises the primary classes for which the limited data on environmental occurrence and effects on nontarget species can be found, in a highly fragmented, disjointed, and disparate literature.
Pharmaceutical drugs are chemicals used for diagnosis, treatment (cure/mitigation), alteration, or prevention of disease, health condition, or structure/function of the human body. The definition is extended to veterinary pharmaceuticals and can also be applied to illicit (recreational) drugs. It also must be noted that the active ingredient in a drug may or may not be the actual formulated parent compound. For example, prodrugs such as the esters of clofibric acid, a metabolite of certain lipid regulators, are converted from pharmacologically inactive parent Table 1 . Conclusions, potential research needs, and recommendations.
Research needs and recommendations
Of all the aspects of pharmaceuticals in the environment, the one that is perhaps the best developed is chemical identification and quantitation. The trend in pharmaceuticals toward higher potency (e.g., enantiomerically pure drugs) while serving to reduce the burden of pharmaceuticals in the environment will add an additional challenge to the analytical effort required to characterize environmental samples because the required detection levels will be even further lowered from the current ppt-ppb levels. Identification of nontarget (unsuspected) toxicants in complex waste streams by toxicity-directed assay of fractions is insufficient (because of the exponential complexity of stressor-receptor combinations). Direct Table  2 . These chemicals, together with their synthetic precursors and transformation products, are continually released into the environment in enormous quantities as a result of their manufacture, use (via excretion, mainly in urine and feces), and disposal of unused/ unwanted drugs and those that have expired, both directly into the domestic sewage system and via burial in landfills. Although largely unknown, there is evidence that large quantities of prescription and nonprescription, "over-the-counter" (OTC) drugs are never consumed (for any number of reasons) (11) , and many of these are undoubtedly eventually disposed down toilets or via domestic refuse.
A striking difference between pharmaceuticals and pesticides with respect to environmental release is that pharmaceuticals have the potential for ubiquitous direct release into the environment worldwide-anywhere that humans live or visit. Even areas considered relatively pristine (e.g., national parks) are subject to pharmaceutical exposures, especially given that some parks have very large, aging sewage treatment systems, some of which discharge into park surface waters and some of which overflow during wet weather events and infrastructure failures (e.g., Yellowstone National Park) (12, 13 Second, many new drugs are introduced to the market each year; some of these drugs are from entirely, new classes never seen before by the microbiota of an STW. Each of these presents a new challenge to biodegradation. A worst-case scenario may not be unusual the concentration of a drug leaving an STW in the effluent could essentially be the same as that entering. Only the severalfold to multiple order of magnitude dilution when the effluent is mixed into the receiving water, assuming a sufficiently high natural flow, serves to reduce the concentration; obviously, smaller streams have increased potential for having higher concentrations of any PPCP that has been introduced. In general, most pharmaceuticals resist extensive microbial degradation (e.g., mineralization) (10). Although some parent drugs often show poor solubility in water (10), leading to preferential sorption to suspended particles, they can thereby sorb to colloids and therefore be discharged in the aqueous effluent. Metabolites, including breakdown products and conjugates, will partition mainly to the aqueous effluent. Some published data demonstrate that many parent drugs do make their way into the environment (see references cited in Table 2 under "Environmental Occurrence"). Oregon, proposal (20) . The highest concentration in an STW effluent reported by Ternes (18) historically designed to protect the consumer from the obvious threats of pathogens, widely used industrial chemicals, and certain radionuclides. The treatment processes used by state-of-the-art POTWs evolved from the need to remove these limited sets of contaminants. In areas ofwater scarcity, the future will see more and more reuse of treated sewage to meet drinking water needs. This will impose a severe burden on water providers to ensure that all chemical contaminants have been removed to the greatest extent possible. It will also require the ability to identify as many of the plethora of potential chemicals in the upgraded water as possible.
According to the National Research Council (NRC) (25) , more than two dozen major U.S. utilities release so much effluent to receiving waters that when the natural flows are low, the discharged waste composes 50% of the eventual flow. Any residual, unidentified contaminants therefore are diluted 2-fold at best. In more densely populated countries (e.g., United Kingdom), this figure can rise as high as 90% of flow during times of low rainfall (26 (27) ]; this is truer for PPCPs than for pesticides, as the former were generally never designed to have any intended effects on wildlife and therefore any knowledge as to what types of effects to look for is clearly more limited. Can changes in a complex system be predicted from knowledge of a small subset of the underlying components? The second is the question of whether it is necessary to know the spectrum of possible physiologic effects, given a multitude of organisms, or possible mechanisms (modes) of action before looking for and ascribing causation to changes at the population level and higher. Considering this, one can only pose at this time the rhetorical question as to whether the risk posed by the presence of pollutants in complex waste streams (e.g., PPCPs in STW effluents) can be detected/quantified by the use of current toxicity screening tests never designed to embrace the spectrum of end points (some exquisitely subtle) that may be involved. The most conservative approach would be one that captures the coordinated use of toxicity-directed screening and chemistry-directed characterization, feeding the results of each to the other, to better reveal the nature of any stressors.
Although most pharmaceuticals are designed to target specific metabolic pathways in humans and domestic animals, they can have numerous often unknown effects on metabolic systems of nontarget organisms, especially invertebrates. Although many nontarget organisms share certain receptors with humans, effects on nontarget organisms are usually unknown. It is important to recognize that for many drugs, their specific modes of action even in the target species are also unknown. (31) . This has the potential to not only lessen side effects, but for some drugs, the total dosage can be lessened by at least 50%. This could help in reducing the burden on sewage treatment plants. The significance of the industry's switch to optically pure isomers is that the number of metabolites and other SRSs entering the environment will be reduced at least by half, and the use of the active ingredient will also be reduced by at least 50% because the potency will effectively increase. At the same time, however, the trend of pharmaceuticals toward higher potency will increase the difficulty of environmental monitoring because the required detection levels will be lowered.
Synergistic effects andpotentiation: the potentially critical role of "multixenobiotic resistance." The biochemical interactions of drugs, often leading to adverse effects, is well known in humans. Little is known, however, of this interplay in aquatic organisms. The following is provided as an example of the complex potential for adverse drug interactions (one actually leading to increased exposure), as it also illuminates the interwoven pathways that ultimately determine exposure. Mostly during this decade, a new mechanism for elimination of xenobiotics from organisms (first observed in tumor cells) has been elucidated-multidrug transporters. This excretory system, also called multixenobiotic transporters, comprises proteins that facilitate the active export of potentially toxic substances, primarily those of moderate lipophilicity, from inside cells. The best-known transporters are the P-glycoproteinlike (Pgp) transporters (P is for permeability altering), or P170 (because of their 170-kDa mass), which have been well characterized in mammals, especially tumor cells, and bacteria.
The toxicologic significance of these nonspecific transporters in maintaining a first line of defense against exposure to multiple xenobiotics in aquatic species has been largely pioneered and reviewed by Epel (32) (32) , as the toxicant cannot be readily removed from the exposed organism; exposure time is thereby lengthened by its intracellular accumulation. This elimination system does not function for highly hydrophobic substances (e.g., DDT, polychlorinated biphenyls [PCBs] ) and as such might play a more critical role in eliciting effects from exposure to the less hydrophobic PPCPs. Xenobiotics may irreversibly inhibit (cyclosporine A inhibits ATPase), competitively inhibit (verapamil, quinidine, reserpine at low concentrations or high concentrations of general lipophilic compounds such as petroleum oil), or indirectly modulate (e.g., via phosphorylation) MXR regulation or expression (staurosporine inhibits protein kinase C Pgp regulator), resulting in its reversal.
The slow escalation, by induction or genetic enrichment, of MXR occurrence and activity among aquatic organisms can give the illusion that the toxicity potential in the aquatic environment is stable or even decreasing when in reality it may be increasing. The introduction of a new substance, at what would normally be a no-effect level, that disrupts the activity of MX1R could thereby lead to a profound cascade of unanticipated and unaccounted-for toxic events-a phenomenon akin to what is being termed toxicantinduced loss of tolerance in humans. Organisms in an aquatic environment that have adapted via MXR to certain levels of a suite of toxicants could experience widespread interspecies toxic events should their MXR be inhibited by the addition of a single agent capable of inhibiting MXR, even one that ordinarily would elicit no effect on its own. The resulting effects would be inexplicable if considered solely on the basis of exposure to the new toxicant.
Little is known about which xenobiotics have activity within this relatively newly identified class of chemicals, referred to as chemosensitizers, or their frequency of occurrence in the environment. Smital and Kurelec (35) , however, showed that unidentified agents in samples from polluted waters enhance the accumulation of aromatic amines Environmental Health Perspectives * Vol 107, Supplement 6 * December 1999 in clams, mussels, snails, and sponges. Some examples of known MXR inhibitors (34, 35) , other than verapamil include trifluoroperazine (Stelazine, which is a calmodulin antagonist and an antipsychotic tranquilizer), reserpine (antihypertensive), quinidine and amiodarone (anti-arrythmics), cyclosporins (immunosuppressants), anthracyclines (noncytotoxic cytotoxin analogs), and progesterone (steroid); some natural substances such as agent(s) in grapefruit juice are also known to inhibit the P-glycoprotein system (36).
Environmental Studies on Pharmaceuticals
Given the numbers and quantities of pharmaceuticals manufactured and used throughout the world and that many of these chemicals are designed to have profound physiologic effects, comparatively little research has been published on their occurrence in the environment, effects on nontarget organisms, or assessment of environmental impact. Literally thousands of distinct drugs are approved for use throughout the world. Many of these are manufactured and used in very large quantities. The world's combined literature (the vast majority of these studies have originated in Europe, but the issue applies equally worldwide) has addressed only a very small percentage of these compounds, and the huge array of associated metabolites and other transformation products, many of which undoubtedly have strong physiologic activity, simply compounds the magnitude of the problem.
When drugs are detected in the environment (e.g., surface waters), their concentrations are generally in the ng/L-ig/L (ppt-ppb) range. Although parts-per-billion concentrations may not pose much acute risk, it is completely unknown whether other receptors in nontarget organisms are sensitive. It must also be recognized that even though individual concentrations of any drug might be low, the combined concentrations from drugs sharing a common mechanism of action could be substantial. Exposures in the aquatic environment are of particular concern, since aquatic organisms (as opposed to those spending at least some time in terrestrial settings) are subject to continual, unabated lifecycle exposures. This is a highly significant consideration for pharmaceuticals (or bioactive metabolites) that are refractory to structural transformations and are continually introduced into surface waters from sewage treatment plants. Moreover Ternes (18) .
The distribution of pharmaceuticals is a large function of their production volumes, which can rival those for many pesticides. There are thousands of registered drugs that are dispensed both as prescriptions and OTC; this makes it difficult to estimate usage rates for those pharmaceuticals sold via both routes (e.g., many analgesics). In Germany, roughly 2,900 drugs are permitted in human medicine alone (18) . Many countries dispense drugs in the absence of prescriptions. The two primary sources for release into the environment are from human and veterinary applications. Ternes (18) states that at least for lipid regulators and NSAIDs the source is almost entirely from human usage, as these drugs are infrequently (or never) used in veterinary medicine. In general, the literature shows that most pharmaceuticals, when detected, are present in surface waters in a concentration range of 1 ng/L-1 pg/L. To put this in perspective, Richardson and Bowron (40) These organisms in turn could suffer effects themselves from exposure or, alternatively, pass on accumulated residues further up the food chain. All other routes of dispersal to other environmental compartments also play roles, with the distinct exception of direct volatilization, because nearly all PPCPs, with the exception of medical gases and fragrances in contrast with many other anthropogenic compounds are polar or otherwise nonvolatile. The major volatile pharmaceuticals are the inhalable anesthetics (e.g., halothane); these hydrofluoroalkanes are known to oxidize in the atmosphere, like the conventional hydro[chloro]fluorocarbon refrigerants, to yield the highly persistent, toxic, and ubiquitous product trifluoroacetic acid (TFA). This source ofTFA is believed to be minor (44 Although the synthetic oral contraceptive (170x-ethynylestradiol) occurs generally at low concentration (< 7 ng/L) in POTW effluent, it is still suspected, in combination with the steroidal estrogens 173-estradiol and estrone [30] , of causing vitellogenin production (feminization) in male fish. Feminization is a phenomenon first observed for fish in sewage treatment lagoons in the mid-1980s (26) . An overview of pharmaceutical hormones in the environment is presented by Arcand-Hoy et al. (51) . The estrogenic activity of various waters (from sewage to drinking water) has been shown to vary dramatically, spanning six orders of magnitude. Some other widely used synthetic hormone modulators include Proscar/Propecia (finasteride: an androgen hormone inhibitor) and various thyroxine analogs (thyroid hormones); nothing is known of the environmental fates of these compounds. In general, the lipophilicity of these hormones is sufficiently great that at least a large portion are removed via sorptive processes in sewage treatment (52, 53) and therefore partition to the sludge; but even the low concentrations that remain in the effluents may be capable of exerting physiologic effects in aquatic biota.
In addition to these synthetic steroids and xenoestrogens is a suite of naturally occurring estrogen hormones, for example, phytoestrogens such as the complex series of leguminous isoflavonoids, including genistein, daidzein, and glycitein in soy. Further complicating the picture are a host of newly suspected endocrine-disrupting compounds (EDCs), more recently referred to as hormonally active agents (HAAs) by the NRC (29) , which have gained attention in the last few years, primarily as a result of the 1996 publication Our Stolen Future by Colburn et al. (54) . These inadvertent EDCs include such commonly recognized industrial pollutants and products as halogenated dioxins/furans, PCBs, organohalogen pesticides, phthalates, and bisphenol A.
The issue of screening many of the major commercial chemicals (over 87,000 total) for endocrine disruption potential has been formalized with the creation of the EDSTAC, which had been charged by the U.S. EPA with the task of implementing a screening and testing program by August 1999 (45) . The Chemical Manufacturers Association (CMA) also has launched an intensive health effects investigation for over 3,000 high-volume chemicals (called the Health and Environmental Research Initiative) (55) . It is significant, however, that pharmaceuticals are not specifically targeted by the EDSTAC (or the CMA) in its tiered screening program that focuses on pesticides, commodity chemicals, naturally occurring nonsteroidal estrogens (phytoestrogens and mycotoxins), food additives, cosmetics, nutritional supplements, and representative mixtures (for possible synergistic effects). Even though the strategy gives top priority to "chemicals with widespread exposure at the national level" (55), PPCPs are not specially targeted. It is also significant that the screening strategy will initially focus on only the three primary hormone systems-estrogen, androgen, and thyroid-hormone systems of relatively unknown importance to invertebrates (45) .
A controversial hypothesis regarding multiple toxicants (sharing a common mode of action), when each is present at a low level, is that of synergism. Evidence of synergism among estrogenic mimics (where the effect can be elicited at orders-of-magnitude lower concentration than predicted by additive action) was reported by Arnold et al. (56) . This study created much controversy by purporting synergistic action of low-level chemical mixtures. Subsequent studies by Gaido et al. (57) and others rebutted this hypothesis. They did not find any evidence of synergism in mixtures of mild estrogenic pollutants.
McLachlan (58) (60, 61) , a polybenzimidazole that activates the receptor for a cytokine that regulates white blood cell production, perhaps portends the advent of many synthetic hormone mimics in therapeutic medicine. If the finding can be generalized, it could mean that the possible routes of hormone disruption by simple molecules could extend beyond that of the estrogen/ androgen system.
With the exception of estrogenic mimics, the possibility of disrupting the activity of proteinaceous hormones by lower molecular weight anthropogenic chemicals has been held in low regard. This view has been based on the fact that a relatively large, complex proteinaceous molecule (the hormone) neatly "fits" within the complex three-dimensional domain of its target receptor, whereas in contrast a much smaller nonproteinaceous molecule would have little to offer in terms of recognition specificity. It has been believed that the complexity of larger proteins such as insulin was required to enable recognition by the corresponding receptors; smaller compounds simply did not convey enough three-dimensional information to have high-binding constants for one or multiple receptors.
The report by Tian et al. (60) demonstrates for the first time that a relatively small nonpeptide molecule can bind to a receptor normally dedicated to a proteinaceous hormone. While this has high therapeutic significance (this research might catalyze concerted attempts to develop the first proteinmimicking and therefore perhaps hormonemimicking low molecular weight drugs), it also alludes to the possibility that existing anthropogenic compounds might have a greater chance of interacting with hormone receptors than was previously believed. Although the synthetic substance was three to six orders of magnitude less potent, its ability to bind to the receptor was undisputed (in the mouse in vitro and, more importantly, in vivo).
Antibiotics
In addition to pathogen resistance, genotoxicity may be a concern. A large body of literature exists on antibiotics in the environment. Veterinary and animal husbandry, especially aquaculture, usage plays a major role in their introduction into the environment. In one study of hospital effluent, fluoroquinolones was the chemical class contributing the major portion to overall DNA toxicity (62); ciprofloxacin, for example, was identified at pg/L. Hirsch Recently, a number of stream surveys documented the significant prevalence of native bacteria that display resistance to a wide array of antibiotics including vancomycin (64) . Isolates from wild geese near Chicago, Illinois, are reported to be resistant to ampicillin, tetracycline, penicillin, and erythromycin (65) . All these reports could simply indicate that the natural occurrence of antibiotic resistence in native bacterial populations is much higher than expected or that these bacteria are being selected for by the uncontrolled release of antibiotics into the environment. If the latter is true then, excluding the significance of antibiotics themselves in the environment, their occurrence can be viewed as marking or indicating the possible presence of other PPCPs.
Blood Lipid Regulators
Fibrates-high usage. Fibric acid metabolites-ubiquitous, persistent pollutants. Clofibric acid was the first prescription drug (actually an SRS) reported in a sewage effluent (37, 39) , and it continues to be one of the most frequently reported PPCPs in monitoring studies. Clofibric acid (2-[41-chlorophenoxy-2-methyl propanoic acid), the active metabolite from a series of widely used blood lipid regulators, and which also happens to be structurally related to the phenylalkanoic acid herbicide mecoprop (the methylphenoxy structural analog), has captured much attention from investigators in Europe. Stan Bea-Blockers/f2-SympathomimetiCs Hirsch et al. (73) and Ternes (18) Fenfluramine (N-ethyl-a-methyl-3-[trifluoromethyl] benzene ethanamine hydrochloride), known as Pondimin in addition to other brand names, is a sympathomimetic amine, which was used as a popular diet (anorectic) drug and was removed from the U.S. market in 1998 by the FDA because of heart valve damage. Although no one has looked for fenfluramine in sewage, it is known to enhance the release of serotonin (3-(2-aminoethyl)indol-5-ol or 5-hydroxytryptamine creatinine sulfate ); in the crayfish, 5-HT in turn triggers release of ovary-stimulating hormone, resulting in larger oocytes with enhanced amounts of vitellin (consequences unknown) (74) . Similarly, in fiddler crabs, fenfluramine at a dose of 125 nmol stimulates (through 5-HT) the production of gonad-stimulating hormone, which accelerates testicular maturation (75) .
Antdepressant/Obsessive-Compulsive Regulators
Subtle but possibly profound effects on nontarget [aquatic] species. Selective serotonin reuptake inhibitors (SSRls) are a major class of widely prescribed antidepressants that includes Prozac, Zoloft, Luvox, and Paxil. These drugs enjoy widespread and heavy use. One of the few series ofstudies reported in the literature that addresses the effects of drugs on nontarget organisms (albeit not the intent of the studies) was performed in a quest for more effective spawning inducers for economically important bivalves (76) . Fong's studies and those of other physiologists studying the function of serotonin in a wide array of aquatic creatures could prove highly significant in any discussion of the importance of low levels of pharmaceuticals in the environment. Fong's work is perhaps the most significant to date for showing the potential for dramatic physiologic effects on nontarget species (in this case invertebrates) by low (ppb) concentrations of pharmaceuticals.
Serotonin is a biogenic amine common in both vertebrate and invertebrate nervous systems. SSRIs increase serotonin neurotransmission by inhibiting its reuptake at the synapses by inhibiting the transporter enzymes. In addition to playing a key role in mammalian neurotransmission, serotonin is involved in a wide array of physiologic regulatory roles in molluscs, among most other creatures. For bivalves, reproductive functions including spawning, oocyte maturation, and parturition are regulated by serotonin, (76) . Serotonin controls a wide spectrum of additional behaviors and reflexes in molluscs, including heartbeat rhythm, feeding/biting, swimming motor patterns, beating of cilia, and induction of larval metamorphosis (77) . It also stimulates release of various neurohormones in crustaceans (hyperglycemic hormone, red pigment-dispersing hormone, neurodepressing hormone, and molt-inhibiting hormone) and ovarian maturation (78) .
It has long been known that serotonin at concentrations of 10A to 10-3 M (-0.18-1.8 g/L) induces spawning in bivalves. Some commercial farmers make use of this by adding serotonin to induce spawning. Fong (76) found that Prozac (fluoxetine) and Luvox (fluvoxamine) are the most potent inducers ever found, eliciting spawning behavior in zebra mussels at aqueous concentrations many orders of magnitude lower than serotonin. Fluoxetine elicited significant spawning in male mussels at concentrations of 10-7 M (-150 pg/L); females were an order of magnitude less sensitive at 10-6 M.
Fluvoxamine was the most potent of the SSRIs, eliciting significant spawning in male mussels, at 10-9 M (40.318 pg/L); females were two orders of magnitude less sensitive, at 10-7 M. In males, spawning was complete in the first hour, while females were slower (within 2 hr). Paxil (paroxetine) was the least potent of these three SSRIs, eliciting male spawning, but to a lesser degree, at 10-M, and having no inducing effect on females at any concentration. It should be noted that Fong states that the evidence is not clear whether these compounds are indeed acting as SSRIs, or via some other mechanism. It is also unknown how these compounds are taken up by molluscs (76) . In another study, Fong et al. (79) showed that fluvoxamine induces significant parturition in fingernail dams at 1 nM; 1 nM fluvoxamine also potentiated the effect of 10 pM 5-HT by almost 5-fold. Paroxetine was less potent, requiring a concentration of 10 pM to effect significant parturition. In contrast, even at concentrations of 100 pM, fluoxetine displayed no effect, although it was capable at 5 pM of potentiating 5-HT at concentrations that were otherwise subthreshold. It is interesting that the order of potency for inducing parturition in clams differs from the order for induction of spawning in mussels (above). This points to the complexity of considering any approach involving extrapolations from one species to another or from one drug to another within a given class.
In crustaceans, Kulkarni et al. (74) found that fluoxetine significantly potentiates the effect of 5-HT in crayfish, enhancing the release of ovary-stimulating hormone, which results in larger oocytes with enhanced amounts of vitellin; any ecologic consequences of higher vitellin protein levels are unknown. Similarly, in fiddler crabs, fluoxetine at a dose of 125 nmol stimulates (through 5-HT) the production of gonad-stimulating hormone, which accelerates testicular maturation (75) .
It is clear that aquatic life can be exquisitely sensitive to at least some of this class of compounds. Although some SSRIs are extremely potent, others have almost no effect, which possibly makes the approach of assessing ecologic risk on a class-by-class basis infeasible.
Concentration of SSRIs plays a complicated role with respect to effects. For example, Couper and Leise (77) found that while injected fluoxetine induced significant metamorphosis in a gastropod, 10-4 M induced less metamorphosis than 10-6 M. Simple extrapolations of effects from higher concentrations do not necessarily have any relevance to effects at lower concentrations.
The potential for SSRIs to elicit subtle effects on aquatic life is further extended by serotonin reuptake mechanisms that also are a factor in snails and squids (76) , particularly in the regulation of aggression (80) . Yet another example of a subtle effect that would go unnoticed is the fighting behavior of lobsters, in which serotonin causes behavior reversal by stimulating subordinates to engage in fighting against dominants by reducing their propensity to retreat (80) .
Antiepileptics
Antiepileptics are ubiquitous andprevalent due to poor STW removal. Carbamazepine was the drug detected most frequently and in highest concentrations during a study by Ternes (18) . This drug was detected in all POTWs and receiving waters, with a maximum concentration of 6.3 pig/L. Ternes hypothesized that the ubiquitous occurrence resulted from the very low removal efficiency from POTWs, which was calculated to be only 7%. Sacher et al. (81) 43 ng/L; median, 6.5-9.3 ng/L). Kiimmerer et al. (83) found ifosfamide to be totally refractory to removal by POTWs and to totally resist alteration during a 2-month bench-scale POTW simulation.
Another class of antineoplastics, the platinates, includes carboplatin and cisplatin. Although the stability of these compounds in sewage systems is unknown, Kummerer et al. (84) calculated that if they were present in hospital sewage effluents as the intact parent compound, they could be present at daily average concentrations of up to 600 ng/L (on the basis of total platinum). Although the majority of the dose for these compounds is excreted in the urine in the first day, a large amount (-30%) resides in the body and is slowly excreted over a period of years and therefore could be excreted to residential sewage systems. Falter and Wilken (85) showed that while these compounds are difficult to determine analytically, their potential to remain in the aqueous phase after sewage treatment is high. White and Rasmussen (86) , in the most detailed overview to date on the genotoxicity of wastewaters, elaborate that while the genotoxic potency of industrial wastewaters is often the highest, the overall loading of genotoxic compounds to surface waters is far greater, up to several orders of magnitude, from municipal treatment plants. They present a striking correlation between the occurrence of direct-acting mutagens in surface waters and the human population served by the discharging STWs. This correlation points to the activities/metabolism of humans, not industrial activities, as the origin for these mutagens. A number of possible sources for the mutagens are discussed, an obvious one of which is antineoplastic drugs.
These data point to antineoplastics as a class of drugs of potential concern for environmental effects, not just for their acute toxicity but perhaps more for their ability to effect subtle genetic changes, the cumulative impact of which over time can lead to more profound ecologic change. Hospitals are the major source of genotoxic drugs. POTWs that service hospitals, especially multiple hospitals, are likely candidates for releasing these chemicals into surface waters.
Impotence Drugs
This class ofdrugs displays widespread use, new modes ofaction, and unknown effects on nontarget organisms. Even though a number of drugs from various chemical classes have been used over the years for treating impotence, the emergence of Viagra (sildenafil citrate) has focused tremendous attention on this market. The significance of this therapeutic class of drugs, with new ones awaiting FDA approval, is that they all tend to have distinct modes of action, most of which differ from those of traditional drugs. While potential effects on wildlife are totally unknown, the fact that Viagra, for example, works by inhibiting a phosphodiesterase responsible for regulating the concentration of cyclic guanosine monophosphate, which indirectly relaxes muscles and increases blood flow (87) , gives cause for concern regarding the disruption of this common phosphodiesterase in unintended target species. Impotence drugs will prove to have very high usage rates, especially since they are one of the most common drugs available without prescription over the Internet, yielding high potential for environmental exposure and possibly nontarget effects.
TranqulAizers
Little is known about possible occurrence of tranquilizers. Ternes (18) reported diazepam in almost half of the POTWs but only in low concentrations of less than 0.04 pg/L; it could not be detected in surface waters. Genicola (88) reports diazepam in the groundwater from a monitoring well at a Superfund site near Atlantic City, New Jersey. Concentrations were approximately 10-40 pg/L and probably originated in a landfill in which pharmaceutical manufacturers disposed of chemicals.
Retinoids
High usage rates andprofound activity in amphibians lends cause for concern. Retinoids, low molecular weight lipophilic derivatives of vitamin A, can have profound effects upon the development of various embryonic systems (89) , especially amphibians in which retinoic acid receptors have been hypothesized to play a role in frog deformities. Although naturally occurring, retinoids have been used for a number of years for a wide array of medical conditions including skin disorders (e.g., Accutane [isotretinoin] for acne), antiaging treatments (e.g., Retin-A [tretinoin] for skin wrinkles), and cancer (e.g., Vesanoid [tretinoin] for leukemia). Isotretinoin (13-cisretinoic acid) is related to both retinoic acid and retinol (vitamin A). Tretinoin is among the top 200 prescribed drugs in the United States. Methoprene, an insecticidal synthetic retinoic acid mimic, is photolabile and yields numerous photo-products, some of which also elicit strong retinoic acid activity (90) . Although retinoic acids would also be expected to be photolabile (and therefore not persistent), their products may also still possess receptor activity.
Diagnostic Contrast Media
Diagnostic contrast media have very high usage rates, display considerable persistence, show no evidencefor mineralization, and have low physiologic activity. Detailed X-ray images of soft tissues are routinely captured by the use of contrast media. Some of the more widely used members of contrast media are highly substituted and sterically hindered amidated, iodinated aromatics such as diatrizoate and iopromide (91) , which are used worldwide at annual rates exceeding 3,000 tons. Kalsch (91) found these compounds to be quite resistant to transformation in STWs and in river waters. When transformations were effected, they merely terminated with unidentified resistant metabolites. Ternes et al. (92) recently reported significant amounts of iopromide in rivers.
In municipal STW effluents, Ternes et (93) also found no acute toxicity for bacteria (Vibrio fisheri), algae (Scenedesmus subspicatus), crustaceaens (Daphnia), and fish (Danio rerio, Leuciscus idus melanotus) exposed to no more than 10 g/L of iohexol, iotrolan, diatrizaote, or iopromide.
Personal Care Products in the Environment
For the purposes of this review, personal care products are defined as chemicals marketed for direct use by the consumer (excluding OTC medication with documented physiologic effects) and having intended end uses primarily on the human body (products not intended for ingestion, with the exception of food supplements). In general, these chemicals are directed at altering odor, appearance, touch, or taste while not displaying significant biochemical activity. Most of these chemicals are used as the active ingredients or preservatives in cosmetics, toiletries, or fragrances. They are not used for treatment of disease, but some may be intended to prevent diseases (e.g., sunscreen agents). In contrast to drugs, almost no attention has been given to the environmental fate or effects of personal care products-the focus has traditionally been on the effects from intended use on human health. Many of these substances are used in very large quantities frequently more than recommended. Personal care products differ from pharmaceuticals in that large amounts can be directly introduced to the environment. For example, these products can be released directly into recreational waters or volatilized into the air (e.g., musks). Because of this direct release they can bypass possible degradation in POTWs. Also, in contrast to pharmaceuticals, less is known about the effects of this broad and diverse class of chemicals on nontarget organisms, especially aquatic organisms. Data are also limited on the unexpected effects on humans. For example, common sunscreen ingredients, 2-phenylbenzimidazole-5-sulfonic acid and 2-phenylbenzimidazole, can effect DNA breakage when exposed to UV-B (94) .
The quantities of personal care products produced commercially can be very large. For example, in Germany alone the combined annual output for eight separate categories has been estimated (95) at 559,000 tons for 1993 (Table 3) . A few examples are given below of common personal care products that are ubiquitous pollutants and that may possess substantial bioactivity.
Fragrances (musks) are ubiquitous, persistent, bioaccumulativepollutants that are sometimes highly toxic; amino musk transformation products are toxicologically significant. Synthetic musks comprise a series of structurally similar chemicals (which emulate the odor but not the structure of the expensive, natural product from the Asian musk deer) used in a broad spectrum of fragranced consumer items, both as fragrance and as fixative. Included are the older, synthetic nitro musks (e.g., ambrette, musk ketone, musk xylene, and the lesser known musks moskene and tibetene) and a variety of newer, synthetic polycyclic musks that are best known by their individual trade names or acronyms. The polycyclic musks (substituted indanes and tetralins are the major musks used today, accounting for almost two-thirds of worldwide production) and especially the inexpensive nitro musks (nitrated aromatics accounting for about one-third of worldwide production) are used in nearly every commercial fragrance formulation (cosmetics, detergents, toiletries) and most other personal care products with fragrance; they are also used as food additives and in cigarettes and fish baits (96) .
The nitro musks are under scrutiny in a number of countries because of their persistence and possible adverse environmental impacts and therefore are beginning to be phased out in some countries. Musk xylol has proved carcinogenic in a rodent bioassay and is significantly absorbed through human skin; from exposure to combined sources, a person could absorb 240 pg/day (97) . The human lipid concentration of various musks parallels that of other bioaccumulative pollutants such as PCBs (98) . Worldwide production of synthetic musks in 1988 was 7000 tons (96); worldwide production for nitro musks in 1993 was 1,000 tons, two-thirds of which were musk xylene (99) .
Synthetic musks first began to be identified in environmental samples almost 20 years ago (100, 101) . By 1981, Yamagishi et al. (100) had identified musk xylene and musk ketone in gold fish (Carassius auratus langsdorfii) in Japanese rivers and not much later (101) in river water, sewage, marine mussels (Mytilus edulis), and oysters (Crassosterea gigas). Yamagishi's studies comprised the first comprehensive monitoring efforts, identifying musk xylene and musk ketone in freshwater fish, marine shellfish, river water, and STW waters. Musk xylene was found in all samples, and musk ketone was found in 80% of the 74 samples analyzed. Concentrations in STW effluents ranged from 25 to 36 ng/L for musk xylene and from 140 to 410 ng/L for musk ketone. Concentrations of musk xylene in fish muscle were in the tens of parts per billion, whereas those for musk ketone were less than 10 pg/kg, with highest values occurring in fish downstream of STWs. In contrast, for shellfish the concentrations were lower, between 1 and 5.3 pg/kg, presumably because of their lower lipid contents. In river water, musk xylene occurred in all samples, whether upstream or downstream of STWs and ranged between 1 and 23 ng/L; those of musk ketone were generally in the same range, but in distinct contrast they were not detectable in upstream samples. Geyer et al. (102) have published an excellent review on residues of nitro musk fragrances in fish and mussels as well as in breast milk and human lipids and the current ecotoxicologic and toxicologic knowledge for these personal care products. Residues of musk xylene and musk ketone found in the fillet of freshwater fish (e.g., pike, eel, brass, Zander, rainbow trout) from rivers of North Germany were between 10 and 350 pg/kg lipid and 10 and 380 pg/kg lipid for musk xylene and musk ketone, respectively. In mussels (Mytilus edulis) pg/kg lipid of both fragrances were detected. In human breast milk from German women, musk xylene and musk ketone were detected between 10 and 240 mg/kg lipid (102) . Recently, the literature has a number of additional publications from Europe, especially Germany and Switzerland. Rimkus et al. (103) give a brief overview of the occurrence of musks in the environment. Kafferlein et al. (99) and Geyer et al. (102) published the most thorough reviews to date on the occurrence (in the environment and in personal care products), transformation, and toxicology of the ubiquitous musk xylene; these reviews summarize many more occurrence studies (for musk xylene) than mentioned here.
Musks are refractory to biodegradation (other than reduction of nitro musks to amino derivatives), which explains why they have been measured in water bodies throughout the world (96 These higher values exceeded those for all the polychlorinated organics and the PAHs. The occurrences of individual musks are sometimes correlated as a result of their use as mixtures in commercial products. In Germany, the nitro musks are being replaced by the polycyclic musks, therefore resulting in lower concentrations for musk ketone (104) .
It is not surprising that musks have been detected in air. Kallenborn et al. (109) detected three polycyclic musks and two nitro musks in Norwegian outdoor air samples. The polycyclic musks were more prevalent. Concentrations of all these musks ranged from low picograms per cubic meter to hundreds of picograms per cubic meter. The most common was the polycyclic musk Galaxolide, but the relative ratios among the musks are a function of usage (which varies among countries) and photolability.
Although the significance of the aquatic toxicity of the nitro and polycyclic musks is debatable [genotoxicity from the polycyclics seems to not be a concern) (110), the aminobenzene (reduced) versions of the nitro musks can be highly toxic; these reduced derivatives are undoubtedly created under the anaerobic conditions of sewage sludge digestion. Behecti et al. (111) Recently, the amino transformation products of nitro musks were identified in sewage treatment effluent and in the Elbe River, Germany. Gatermann et al. (96) identified musk xylene and musk ketone together with their amino derivatives 4-and 2-amino musk xylenes and 2-amino musk ketone. In sewage treatment influent, the concentrations of musk xylene and musk ketone were 150 and 550 ng/L, respectively. In the effluent, their concentrations dropped to 10 and 6 ng/L, respectively. In contrast, although the amino derivatives could not be detected in the influent, their concentrations in the effluents dramatically increased, showing extensive transformation of the parent nitro musks: 2-amino musk xylene (10 ng/L), 4-amino musk xylene (34 ng/L), and 2-amino musk ketone (250 ng/L). It was concluded that the amino derivatives could be expected in sewage effluent at concentrations more than an order of magnitude higher than the parent nitro musks. In the Elbe, 4-amino musk xylene was found at higher concentrations (1-9 ng/L) than the parent compound.
Given that the amino nitro musk transformation products a) are more water soluble than the parent musks, b) still have significant octanol-water partition coefficients (high bioconcentration potential), and c) are more toxic than the parent nitro musks, more attention should be focused on these compounds. Because synthetic musks are ubiquitous, used in large quantities, introduced into the environment almost exclusively via treated sewage effluent, and are persistent and bioconcentratable, they are prime candidates for monitoring in both water and biota as indicators for the presence of other PPCPs.
Their analysis, especially in biota, has been thoroughly discussed by Gatermann et al. (96) and by Rimkus et al. (103) . Preservatives Parabens (alkyl-p-hydroxybenzoates) are one of the most widely and heavily used suites of antimicrobial preservatives in cosmetics (skin creams, tanning lotions, etc.), toiletries, pharmaceuticals, and even foodstuffs (up to 0.1% wt/wt). Although the acute toxicity of these compounds is very low, Routledge et al. (112) report that these compounds (methyl through butyl homologs) display weak estrogenic activity in several assays. Although the risk from dermal application in humans is unknown, the probable continual introduction of these benzoates into sewage treatment systems and directly to recreational waters from the skin leads to the question of risk to aquatic organisms. Butylparaben showed the most competitive binding to the rat estrogen receptor at concentrations one to two orders of magnitude higher than that of nonylphenol and showed estrogenic activity in a yeast estrogen screen at (122) , which has applied to FDA for various investigational new drug applications. The patenting of hundreds of multiple-molecule nutraceuticals for therapeutic purposes could lead to more widespread use of these substances.
As an example, a recent addition to this class is a substance called huperzine A, an alkaloid extracted from a Chinese moss, which has been documented to improve memory. It is therefore experiencing strong demand for treating Alzheimer's disease and has captured the attention of those who follow the nutraceutical market because of its true pharmaceutical qualities. The significance of this particular compound is that it possesses acute biologic activity as a cholinesterase inhibitor identical to that of organophosphorus and carbamate insecticides. It is so effective that the medical community is concerned about its abuse/misuse, especially since it is legal. While huperzine A, and alkaloids in general (compounds with heterocyclic nitrogen, proton-accepting group, and strong bioactivity), are naturally occurring compounds, their susceptibility to biodegradation in STWs or in open waters is unknown. This is the case for almost all nutraceuticals.
Another example is Kava, which is prepared from the root of Piper methysticum, long used throughout the South Pacific because of its mild narcotic effect among a host of other effects. The active ingredients in Kava are believed to be a suite of lipophilic lactones comprising substituted 0c-pyrones (methysticin, kavain, yangonin, and others) (123) . These compounds display a host of effects in humans, but nothing is known about their effects on other organisms or fate in STWs.
There are countless other nutraceuticals, both new and ancient, experiencing vigorous consumption. These few examples illustrate the unknowns regarding whether these compounds are being excreted, surviving sewage treatment, and then eliciting effects on aquatic organisms. Nutraceuticals and herbal remedies would have the same potential fate in the environment as pharmaceuticals, with the added dimension that their usage rates could be much higher, as they are readily available and taken without the controls of prescription medication. Because these compounds are natural products, however, they would be expected to be more easily biodegraded.
Although the argument can be made that naturally occurring compounds would not pose an ecologic risk, this ignores that a) the concentrations of these compounds in effluents could be higher than they are in the environment in which they occur naturally, and b) many of these substances/mixtures come only from isolated parts of the world (e.g., Kava, huperzine), and their use/dispersal in other parts of the world would essentially make them anthropogenic. The use of these compounds serves to redistribute their normal occurrence in the environment, and even though they might be naturally occurring, this promotes exposure to organisms that normally would never occur. Perhaps the most important concern regarding the exposure of aquatic and terrestrial organisms to PPCPs is that the effects could be so subtle that they would escape any effort to detect them, with the result that imperceptible changes could accumulate until they had a significant impact-not necessarily on the individual organisms but rather on the population or community, perhaps after generations of change. Subtle effects via regulation by any of the countless pathways/ networks of signal transduction in aquatic species can range from modification or reversal of attraction and boldness to avoidance and shyness affecting all behavior characteristics spanning the range from feeding to mating to directional sensing (e.g., chemotaxis, gravitaxis). On the surface, the result would simply be attributed to natural adaptation or confounded by other natural changes.
Kurelec (128) The significance of subtle and cumulative impacts is only beginning to be recognized by environmental toxicologists. Weiss (129) wrote that just as the predicted rise in "crack babies" whose pregnant mothers used cocaine was never observed-rather only a small but significant 3% reduction in IQ was observed-the same subtle effects are very likely occurring from environmental toxicants. Weiss points out that the effects on humans by lead (Pb), methyl mercury, PCBs, and endocrine disruptors in general probably are manifested in almost undetectable changes, and these may accumulate over time to yield truly profound changes that would not be distinguishable from natural events. The specter of subtle, cumulative effects could make current toxicity-directed screening largely useless in any effort to test waste effluents for toxicologic end points.
Abnormal behavior can masquerade as seemingly normal deviation within a natural statistical variation. Change can occur so slowly that it appears to result from natural events, with no reason to presume artificial causation. It is difficult to connect the issues of cause and ultimate effect, in part because of the ambiguous and subjective nature of subtle effects, but especially when these effects are confounded as aggregations of numerous, unrelated interactions. Weiss (130) points out that statistical tests based on means and p values are incapable of detecting the very subtle changes that low-level toxicants can impart. Slight shifts within the statistical distributions of any particular characteristic expressed among a population are not necessarily reflected by statistics of the mean/median; these changes may well be more obvious, however, when considering an individual organism rather than looking across a population.
Another aspect to gradual, undetected changes relates to community composition/ organization, especially in microorganisms, in which the composition of species can be affected over time (i.e., successional effects) as a result of the presence of anthropogenic chemicals (131) . The pressure for succession can result from adverse effects (e.g., toxicity preferentially to one species over another) or from conferring an advantage to one species (e.g., use of the toxicant as a nutrient source). Succession of community structure tends to occur on such a long time line that cause and effect issues are rarely considered.
A number of toxicity testing approaches have been developed over the years, some of which employ less obvious end points for the nonspecific detection of the presence, but not the identities, of toxicants. One of the best known rapid approaches uses the reduction in light output of a bioluminescent bacterium (e.g., Microtox) (132) . Another more recent example (133) automatically detects changes in the gravitaxis of a unicellular flagellate-indeed, a subtle end point in itself and one that would probably go unnoticed and undoubtedly lead to die off. Such approaches are badly needed for detecting changes in toxicant concentrations in wastewater effluents and for directing subsequent chemical characterization to identify the putative toxicants.
Environmental Assessment
Although various levels of prospective ERA via standardized tests are required in the United States and Europe as part of the drug registration process (see "Approach of Regulatory Agencies" below), meaningful effort on this front is simply not possible with the currently limited state of knowledge on environmental fate, transport, and effects of pharmaceuticals; to date, retrospective studies (e.g., ERAs based on environmental survey) are rare. Examples of prospective ecologic assessments can be seen in Henschel et al. (28) , who performed these assessments for four high-use pharmaceuticals in Germany: salicylic acid (the main metabolite of acetylsalicylic acid, aspirin), paracetamol (4-acetamidophenol, acetominophenanalgesic/antipyretic), clofibric acid (chlorophenoxyisobutyric acid; blood lipid regulator), and methotrexate (4-amino-10-methyl-folic acid; chemotherapy folic acid antagonist that disrupts nucleotide synthesis). Unmetabolized, the loading of these drugs into bodies of water in Germany could be hundreds of tons per year. Henschel et al. (28) (143) .
Effects testing includes algal growth inhibition, fish acute/chronic/bioaccumulation exposure, avian dietary and reproductive, earthworm toxicity, terrestrial plant growth, and activated sludge respiration inhibition. The guidance document seems to recognize the incredible diversity of stressor-receptor possibilities that could result from pharmaceuticals and their metabolites entering the environment: "there may be considerable variation in receptor specificity/ sensitivity between species" (143) . This is complicated further by the fact that the mode(s) of action responsible for the desired therapeutic effect of many drugs is poorly understood (sometimes totally unknown). For example, although various modes of action for the disease-modifying agents used to treat rheumatoid arthritis (e.g., methotrexate and hydroxychloroquine, intended for use in chemotherapy and malaria, respectively) have been known for many years, the actual mechanisms by which the symptoms of this particular disease are alleviated are mostly unknown. It would therefore be impossible to forecast what type of effects could be anticipated.
Biocides. The new EU Biocide Directive (144) covers the commercialization of biocidal products (e.g., disinfectants), but few of these are used in personal care products. Significantly, however, the Directive emphasizes ecotoxicologic issues (on par with human health issues), including fate and ecologic effects.
FDA
Concern regarding introduction of pharmaceuticals to the environment in the United States is addressed by the FDA, which requires Environmental Assessments (EAs), as required under National Environmental Policy Act of 1969) (NEPA), and the specifics of which are set forth in "Guidance for Industry: Environmental Assessment of Human Drug and Biologics Application" (145) for all drug applications/actions meeting minimum criteria. As with the EU's approach, concern rests primarily on acute and chronic effects as measured by traditional toxicity tests. Much less concern is expressed for behavioral effects, whether avoidance, breeding, etc. The FDA does, however, recognize "extraordinary circumstances" where there is the potential for serious harm to the environment or for an action to "significantly affect the quality of the human environment" (145) . This notion includes not just toxicity to environmental organisms but also "environmental effects other than toxicity, such as lasting effects on ecological dynamics" (145) . Clearly this could cover subtle behavioral modifications from which effects accumulate over time/generations, eventually leading to measurable change but unrecognized as such. NEPA [40 CFR 1508.27; also see Appendix C in the FDA document (145) ] also defines "significantly" around two issues-"context" and "intensity" (severity of impact). Among the 10 issues with respect to "intensity," one relates to:
Whether the action is related to other actions with individually insignificant but cuLmulatively significant impacts.
Significance exists if it is reasonable to anticipate a cumulatively significant impact on the environment. The FDA's approach is very similar to that of the EU. The FDA requires an EA if the expected environmental concentration (EEC, analogous to the PEC predicted environmental concentration) at the point of entry to the aquatic environment (the expected introduction concentration [EIC) exceeds 1 ppb. The EIC is calculated assuming that all the drug product produced for 1 year enters POTWs, that the drug's usage is spread across the country in proportion to the population, and that none of the parent drug is metabolized or transformed; this can be altered if transformation data are available, but if metabolites or other SRSs are present at greater than 10% of the parent level, then toxicology must also be known. Its value is calculated as the product of a) kilogram per year of active product produced for use, b) reciprocal of the influent to POTWs (liters per day), c) reciprocal of 365 days/year, and d) 109 pg/kg.
Like the EMEA, the FDA uses a tiered approach to determine if regulatory actions are required. This approach centers around assessment factors used to determine when ecotoxicity testing is not needed. An assessment factor is calculated by dividing the test end point (e.g., lethal dose or EC50) by the maximum EEC (which is equal to the greater of EEC or EIC). Lower factors necessitate more extensive testing. Further testing is also necessitated by drugs that bioaccumulate or with SRSs that are more toxic than the parent drug. The weakest aspect to this approach is that the toxicity of the SRSs is assessed from what is known for human toxicology rather than for potential nontarget organisms. Moreover, given the current knowledge of fate, transport, and ecotoxicity of anthropogenic chemicals, there are simply too many unknowns to be able to predict whether a pharmaceutical (or its transformation products) will find its way into the environment at a particular concentration. The FDA also requires EAs for drugs that also occur naturally in the environment if their usage and subsequent discharge (to POTWs, landfills, etc.) will alter the natural, ambient concentration.
A significant shortcoming of either of these two current regulatory approaches to determining ecologic risk results from not taking into account the cumulative (additive/synergistic/antagonistic) impacts of drugs affecting the same receptors. The EEC value for any given drug could easily be exceeded when the cumulative concentrations of likemode-of-action drugs are considered, especially in those instances where numerous competing drugs are commercially available in any class. Needless to say, this approach also ignores the possibility of synergistic effects from drugs of other classes.
Conclusions and Recommendations
This review aims to catalyze a discussion in the environmental science community to determine the significance of PPCPs in the environment and to foster further research efforts, if warranted. The intent is not to outline a tiered approach for a research strategy, but rather to highlight where further research might be needed in each of various areas organized around the "risk paradigm," as set forth by the National Research Council (146) ( Table 1) . A step-wise strategy to determine if a major research effort needs to be launched would require efforts at establishing the incidence of PPCP occurrence in the environment coupled with parallel determinations of whether effects among a wide spectrum of aquatic organisms can occur at documented concentrations of PPCPs and whether costeffective modifications of STW operation can dramatically improve removal efficiencies. The authors' personal recommendations and summary of significant conclusions are presented in Table 1 . It is hoped that this broad overview presents a wide perspective and proper context for this emerging problem.
